Galcanezumab Effective at Decreasing Monthly Headache Days in Migraine

Approximately 40% of patients with episodic migraine who were treated with galcanezumab achieved 100% response rate for at least 1 month.

Source link

Related posts

Stroke risk factors in couples. A population-based study in community-dwelling adults living in a remote rural setting (the Atahualpa Project)


How To Self-Care While On A ‘Deserted Island’


What's happening in Neurology(R) Genetics


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World